Tag: nuclear imaging
SNMMI Patient Education Day – Hybrid (In-Person and Virtual)
The Society of Nuclear Medicine and Molecular Imaging will offer a special Patient Education Day on Sunday, June 12 as part of its 2022 Annual Meeting. This free event offers patients and caregivers a unique opportunity to learn about the role of nuclear…
READ MORE
Dr. Daniel Lee to Be Featured Guest for CCF’s Luncheon with the Experts
Daniel Lee, MD, Section Chief of Nuclear Medicine at Ochsner Medical Center in Louisiana, will be the featured guest for Facebook Live Luncheon with the Experts on Thursday, February 3, 2022 from 12 noon to 1 pm, Eastern Time. Dr. Lee’s expertise…
READ MORE
3rd Theranostics World Congress Offers Free Patient Program on March 14
Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…
READ MORE
First Northeastern Facility Offers Gallium-68 DOTATOC PET/CT Imaging for Carcinoid and Neuroendocrine Cancer Patients
When Brian Hakimian had the 68Gallium DOTATOC PET/CT scan at the Icahn School of Medicine, Mount Sinai in New York City on January 14, 2015, he became the first carcinoid patient to undergo this novel imaging test at a northeastern facility. Now in clinical…
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORE
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
